Ralf Clemens, a senior executive in the vaccine industry, has been appointed to the supervisory board of CureVac AG, which is developing drugs based on messenger RNA. Dr Clemens has worked at both GSK Biologics and Novartis.
He is being joined on the board by Jean Stéphenne, another GSK Biologicals’ veteran. Mr Stéphenne will represent the Bill & Melinda Gates Foundation, which is a CureVac shareholder. Finally, Chris Tanner, chief financial officer of Cosmo Pharmaceuticals SA, has joined the board. Dr Tanner is a finance professional who previously worked for UBS in Zurich, Switzerland.
CureVac announced the appointments on 18 March 2016.
Copyright 2016 Evernow Publishing Ltd